Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial US$ 22.52 Min. order: 1 piece ★★★★★ 4.5 (203 reviews) Sold : Login>>
Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme US$ 27.05 Min. order: 1 piece ★★★★★ 4.3 (290 reviews) Sold : Login>>
Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug US$ 28.21 Min. order: 1 piece ★★★★★ 5.0 (112 reviews) Sold : Login>>
Novo Nordisk Files NDA for CagriSema, Novel GLP-1-amylin Combination for Chronic Weight Management US$ 29.56 Min. order: 1 piece ★★★★★ 4.1 (19 reviews) Sold : Login>>